HCA Healthcare vs Regeneron Pharmaceuticals

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (88 vs 92)
HCA Healthcare logo

HCA Healthcare

LeaderHealthcare Tech

Enterprise

Largest US for-profit hospital network with ~190 hospitals; $70.7B FY2024 revenue; AI clinical decision support reducing preventable mortality; Sun Belt demographics advantage; NYSE: HCA.

AI VisibilityBeta
Overall Score
A88
Category Rank
#122 of 290
AI Consensus
46%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
99
Gemini
83

About

HCA Healthcare is the largest for-profit hospital system in the United States, founded in 1968 by Jack Massey, Dr. Thomas Frist Sr., and Dr. Thomas Frist Jr. in Nashville, Tennessee, where it remains headquartered and trades on NYSE (HCA). The company operates approximately 190 hospitals and 2,400 ambulatory care sites—including surgery centers, physician clinics, and urgent care facilities—across 20 U.S. states and the United Kingdom, serving over 37 million patients annually. For FY2024, HCA generated approximately $70.7 billion in revenues under CEO Samuel Hazen, continuing a multi-year growth trajectory driven by hospital volume recovery, acuity mix improvement, and strategic investments in ambulatory care that intercept patients in lower-cost settings before they require inpatient hospitalization.

Full profile
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

AI VisibilityBeta
Overall Score
A92
Category Rank
#93 of 290
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
97
Perplexity
92
Gemini
99

About

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Full profile

AI Visibility Head-to-Head

88
Overall Score
92
#122
Category Rank
#93
46
AI Consensus
66
stable
Trend
stable
79
ChatGPT
97
99
Perplexity
92
83
Gemini
99
87
Claude
88
98
Grok
86

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.